Accumulation of CD5+CD19+ B lymphocytes expressing PD-1 and PD-1L in hypertrophied pharyngeal tonsils

Clinical and Experimental Medicine

Volumn 16, Issue 4, 2016, Pages 503-509

  Wlasiuk, Paulina ^a   Niedzielski, Artur ^a   Skorka, Katarzyna ^a   Karczmarczyk, Agnieszka ^a   Zaleska, Joanna ^a   Zajac, Malgorzata ^a   Putowski, Maciej ^a   Pac Kozuchowska, Elzbieta ^a   Giannopoulos, Krzysztof ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

CD5+CD19+ B cells; Chronic antigenic stimulation; PD 1; PD 1L; Tonsillitis

Indexed keywords

CD19 ANTIGEN; CD4 ANTIGEN; CD5 ANTIGEN; CD8 ANTIGEN; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; CD19 MOLECULE, HUMAN; CD274 PROTEIN, HUMAN; PDCD1 PROTEIN, HUMAN; PDCD1LG2 PROTEIN, HUMAN; PROGRAMMED DEATH 1 LIGAND 2;

ADENOID HYPERTROPHY; ADOLESCENT; ADULT; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHILD; CHILDHOOD DISEASE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; ADENOID; IMMUNOLOGY; INFANT; METABOLISM; T LYMPHOCYTE; TONSILLITIS; UPREGULATION;

ADENOIDS; ADOLESCENT; ANTIGENS, CD19; ANTIGENS, CD274; ANTIGENS, CD5; B-LYMPHOCYTES; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; MALE; PROGRAMMED CELL DEATH 1 LIGAND 2 PROTEIN; PROGRAMMED CELL DEATH 1 RECEPTOR; T-LYMPHOCYTES; TONSILLITIS; UP-REGULATION;

EID: 84941347852     PISSN: 15918890     EISSN: 15919528     Source Type: Journal    
DOI: 10.1007/s10238-015-0385-y     Document Type: Article

References (25)

1. Gysin G. Indications of pediatric tonsillectomy. ORL. 2013;75:193–202.
2. van Kempen MJ, Rijkers GT, Van Cauwenberge PB. The immune response in adenoids and tonsils. Int Arch Allergy Immunol. 2000;122:8–19.
3. LeBien TW, Tedder TF. B lymphocytes: how they develop and function. Blood. 2008;112:1570–80.
4. + B-cell. Int J Biochem Cell Biol. 2004;36:2105–11.
5. Balkhi MY, Qiangzhong M, Ahmad S, Junghans RP. T cell exhaustion and interleukin 2 downregulation. Cytokine. 2015;71:339–47.
6. Shinohara T, Taniwaki M, Ishida Y, Kawaichi M, Honjo T. Structure and chromosomal localization of the human PD-1 gene (PDCD1). Genomics. 1994;23:704–6.
7. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010;236:219–42.
8. + T cells from tonsillar tissue. Clin Exp Immunol. 2012;168:200–6.
9. James ES, Harney S, Wordsworth BP, Cookson WO, Davis SJ, Moffatt MF. PDCD1: tissue-specific susceptibility locus for inherited inflammatory disorders. Genes Immun. 2005;6:430–7.
10. Riley JL. PD-1 signaling in primary T cells. Immunol Rev. 2009;229:114–25.
11. Brambilla I, Pusateri A, Pagella F, et al. Adenoids in children: advances in immunology, diagnosis and surgery. Clin Anat. 2014;27:346–52.
12. Graeme-Cook F, Bhan AK, Harris NL. Immunohistochemical characterization of intraepithelial and subepithelial mononuclear cells of the upper airways. Am J Pathol. 1993;143:1416–21.
13. Dalloul A. CD5: a safeguard against autoimmunity and a shield for cancer cells. Autoimmun Rev. 2009;8:349–53.
14. Hayakawa K, Formica AM, Colombo MJ, Ichikawa D, Shinton SA, Brill-Dashoff J, Hardy RR. B cells generated by B-1 development can progress to chronic lymphocytic leukemia. Ann N Y Acad Sci. 2015. doi:10.1111/nyas.12768.
15. Bouaziz JD, Yanaba K, Tedder TF. Regulatory B cells as inhibitors of immune responses and inflammation. Immunol Rev. 2008;224:201–14.
16. Mauri C, Menon M. The expanding family of regulatory B cells. Int Immunol. 2015. dxv038.
17. Nicholas KJ, Zern EK, Barnett L, et al. B cell responses to HIV antigen are a potent correlate of viremia in HIV-1 infection and improve with PD-1 blockade. PLoS ONE. 2013;. doi:10.1371/journal.pone.0084185.
18. Siewe B, Wallace J, Rygielski S, et al. Regulatory B cells inhibit cytotoxic T lymphocyte (CTL) activity and elimination of infected CD4 T cells after in vitro reactivation of HIV latent reservoirs. PLoS ONE. 2014;9:e92934.
19. Grzywnowicz M, Zaleska J, Mertens D, et al. Programmed death-1 and its ligand are novel immunotolerant molecules expressed on leukemic B cells in chronic lymphocytic leukemia. PLoS ONE. 2012;. doi:10.1371/journal.pone.0035178.
20. Zhang G, Li N, Zhang P, et al. PD-1 mRNA expression is associated with clinical and viral profile and PD1 3′-untranslated region polymorphism in patients with chronic HBV infection. Immunol Lett. 2014;1:212–6.
21. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8:793–800.
22. Ishida M, Iwai Y, Tanaka Y, et al. Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues. Immunol Lett. 2002;84:57–62.
23. Speiser DE, Utzschneider DT, Oberle SG, Münz C, Romero P, Zehn D. T cell differentiation in chronic infection and cancer: functional adaptation or exhaustion? Nat Rev Immunol. 2014;. doi:10.1038/nri3740.
24. Lyford-Pike S, Peng S, Young GD, et al. Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res. 2013;73:1733–41.
25. Wu X, Zhang H, Xing Q, et al. PD-1(+) CD8(+) T cells are exhausted in tumours and functional in draining lymph nodes of colorectal cancer patients. Br J Cancer. 2014;111:1391–9.